Cellebrite shares reversed lower on November 12, 2026, after third-quarter results included another trim to the Company's full-year revenue outlook. An investigation into potential securities law violations is underway.
NEW YORK, Nov. 20, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT) shares fell approximately 14% on November 12, 2026, after the Company's third-quarter 2026 report included another trim to its full-year revenue outlook. If you lost money on CLBT shares, you may have legal rights. Shareholders who suffered losses are encouraged to submit your loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Shares opened higher on the November 12 report and then reversed during the session. The latest revenue trim followed a guidance cut in August 2026 and a change in the Company's chief executive officer. Levi & Korsinsky is investigating potential securities law violations on behalf of Cellebrite investors.
Cellebrite reported third-quarter revenue of $149.0 million. For the fourth quarter, the Company guided to revenue of $145 million to $150 million. The midpoint of that range is below the quarter just reported. Full-year annual recurring revenue (ARR) guidance was left unchanged.
If CLBT cost you money, request a review of your losses or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the CLBT Investigation
Q: Who is conducting the CLBT investigation? A: Levi & Korsinsky, LLP is investigating potential securities law claims on behalf of investors who purchased CLBT securities. The firm is nationally recognized and has been ranked in the ISS Top 50 for seven consecutive years.
Q: Who is eligible to participate in the CLBT investigation? A: Investors who purchased CLBT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did CLBT stock drop? A: Cellebrite DI Ltd. (NASDAQ: CLBT) shares fell approximately 14% on November 12, 2026, after the Company's third-quarter 2026 report included another trim to its full-year revenue outlook. Investors who purchased shares and suffered losses may be eligible to have their potential recovery evaluated.
Q: What do CLBT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my CLBT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE Levi & Korsinsky, LLP

Share this article